The GLP-1 market was valued at USD 52.82 billion in 2025 and is projected to grow from USD 58.48 billion in 2026 to USD 133.92 billion by 2034, at a CAGR of 10.9% during 2026–2034, according to Polaris Market Research. Growth is driven by expanding therapeutic applications beyond diabetes, such as obesity and cardiovascular diseases. This article reviews the clinical demand drivers and the treatment formats gaining traction among providers and manufacturers.

How GLP-1 Receptor Agonists Create Clinical Value

GLP-1 (glucagon-like peptide-1) is a hormone-based therapeutic class used to improve insulin secretion and regulate blood sugar levels. It also slows gastric emptying and reduces appetite, which makes it effective for managing type 2 diabetes and obesity. GLP-1 receptor agonists offer dual benefits by improving insulin secretion and suppressing glucagon release in a glucose-dependent manner, which aligns with current clinical management needs. Guidance from organizations such as the American Diabetes Association and the European Association for the Study of Diabetes supports use in specific patient populations, and the ADA's 2026 Standards are expanding the relevance of GLP-1-based therapies in diabetes, obesity, and related metabolic care.

Type 2 Diabetes Prevalence as a Core Demand Driver

Type 2 diabetes prevalence continues to rise worldwide. According to a WHO report cited by Polaris, approximately 830 million people had diabetes in 2022, and over 95% of cases were type 2. The International Diabetes Federation projects 643 million cases by 2030 and 783 million by 2045. The report connects this trend to consumption of highly processed food, sugary beverages, and fast food, which are linked to weight gain and impaired glucose metabolism.

Demographics add to the picture. UN data cited in the report show the global population aged 65 and above rising from 761 million in 2021 to 1.6 billion by 2050, and older adults are highly prone to type 2 diabetes and related conditions.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/glp-1-market 

Obesity Treatment Is the Largest Indication

By target indication, the obesity segment held the largest share in 2025. The report cites a May 2025 WHO report stating that 2.5 billion adults were overweight in 2022, including 890 million living with obesity. Rising clinical acceptance and expanding regulatory approvals for obesity indications reinforced the segment's dominance. Because GLP-1 therapies address both metabolic issues and excess body weight, they are considered well suited to long-term weight management, which positions obesity treatment as a central commercial focus. Partnerships reflect this: in May 2025, CheqUp and WeightWatchers teamed up to offer clinical GLP-1 medication support alongside behavioral lifestyle programs.

Long-Acting and Oral Formats Gain Ground

By type of drug, the long-acting segment dominated in 2025. Long-acting GLP-1 agonists offer superior dosing convenience, improved patient observation, and sustained therapeutic efficacy. These formulations require less frequent administration, often once weekly, which reduces treatment burden and improves long-term compliance.

By route of administration, the oral segment is expected to witness faster growth during 2026–2034. Oral GLP-1 therapies eliminate the need for injections, and improved drug delivery technologies allow effective oral formulations with efficacy comparable to injectable counterparts. The report expects this shift to expand market reach and improve access, especially in primary care settings, and notes that preference for oral options will be high among populations with injection-related hesitations.

Regional Outlook and Key Players

North America dominated in 2025, supported by high disease prevalence and advanced healthcare infrastructure; CDC data cited in the report show diabetes affects 11.6% of the U.S. population. Asia Pacific is projected to record the fastest growth, driven by lifestyle-related diseases and improving healthcare access, with an ICMR study cited as indicating 101 million diabetes cases in India. Europe is projected to record substantial growth, supported by a strong regulatory framework and structured disease management programs. High treatment cost and affordability challenges remain a restraint.

Future Outlook

The GLP-1 Market is expected to experience substantial growth as demand for therapies addressing diabetes and obesity continues to rise. Pharmaceutical companies are investing in next-generation formulations, improved delivery methods, and broader therapeutic applications. Increasing awareness of metabolic health is likely to expand the addressable patient population. Competition among drug developers may encourage innovation and improve treatment accessibility. Pricing, reimbursement, supply capacity, and long-term patient adherence will remain important market factors.

Key players include AstraZeneca, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Roche, Sanofi, and Tonghua Dongbao Pharmaceutical.

More Trending Latest Reports By Polaris Market Research:

Pea Protein Market

Flexible Foam Market

Metalworking Fluids Market

Clindamycin Phosphate Injection Market

Flexible Foam Market

Muscle Stimulator Market

Wetsuit Market- update

Artificial Intelligence in Precision Medicine Market: The Future of Personalized Healthcare

Pizza Oven Market